查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2000597

心血管吻合装置市场：依产品类型、机制、手术类型、外科手术类型及最终用户划分－2026-2032年全球市场预测

Cardiovascular Anastomosis Devices Market by Product Type, Mechanism, Procedure Type, Surgery Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，心血管吻合装置市场价值将达到 21.9 亿美元，到 2026 年将成长至 24.3 亿美元，到 2032 年将达到 46.5 亿美元，复合年增长率为 11.34%。

主要市场统计数据
基准年 2025 21.9亿美元
预计年份：2026年 24.3亿美元
预测年份 2032 46.5亿美元
复合年增长率 (%) 11.34%

对目前心血管吻合术的设备生态系统、临床考量和营运重点进行清晰权威的指南。

心血管吻合装置融合了外科技术、材料科学和系统级医疗服务。本文介绍了目前用于在各种手术中建立和固定血管及心臟连接的工具，揭示了装置的几何形状、作用机制和临床工作流程如何相互作用并影响治疗结果。该领域已从手动缝合发展到机械化、能量辅助和混合解决方案，旨在提高手术的可重复性、缩短手术时间并最大限度地减少併发症。

微创手术的趋势、材料技术的快速发展、器械互通性的提高以及采购模式的演变，正在重新定义外科吻合术的实践。

多项变革正在重塑心血管吻合器材的设计、应用和商业化，并对临床、生产和医保报销等领域产生影响。首先，微创和机器人辅助手术的稳定发展，推动了对能够在有限入路下实现稳定、可重复吻合的器械的需求成长。这一趋势加速了器械在形状、灵活性和与机器人平台整合方面的迭代改进。因此，产品开发现在更加重视模组化介面和相容性标准，以加快临床应用并减轻训练负担。

美国关税趋势变化如何推动供应链重组、价格压力以及本地製造业韧性机会的实证分析。

主要市场政策变化导致的关税征收和提高，可能会对心血管吻合器材製造商和经销商的供应链选择、筹资策略和零件成本产生重大影响。如果进口关税出台或提高，依赖跨境采购精密金属零件、先进聚合物、电控系统或机器人子系统的公司将需要重新评估其供应商关係和库存管理实践，以维持获利能力和供应稳定性。

透过整合产品类型、机制、流程和最终用户参数的多维细分，我们确定了精确的临床和商业性目标领域。

要了解产品和临床细分市场，需要采用多层次的细分方法，以明确哪些领域能够最有效地部署创新和商业化。按产品类型划分，该器械市场包括夹子、缝合器和缝合器械。夹子用于快速控制血管，止血夹和血管夹是典型的例子。止血夹本身有金属和聚合物两种材质，兼顾了耐用性和与影像诊断的兼容性。缝合器有圆形和直线形两种结构，直线形缝合器再依组织厚度和抗渗漏性分为非加强型和加强型。缝合器械涵盖自动缝合和手动缝合技术，其中自动缝合又细分为手持式和机器人缝合器，以满足不同的自动化程度和手术复杂程度的需求。

区域临床重点、法规环境和供应链发展如何对美洲、欧洲、中东和非洲以及亚太地区的医疗设备部署产生不同的影响？

区域趋势塑造了部署路径、监管障碍和供应链设计，进而影响策略和实施。在美洲，临床上对微创冠状动脉和周边血管介入治疗的关注，与成熟的报销体系和完善的医院采购流程相契合。主要市场的医疗机构优先考虑能够显着缩短手术时间、降低併发症率并与现有手术平台相容的器械。同时，区域製造商和契约製造在提供本地化供应和快速补货方面发挥着至关重要的作用，这有利于高运作的医疗机构。

对医疗器材领域的竞争定位、伙伴关係动态、供应商重点以及塑造领导地位的创新路径进行深入分析。

心血管吻合器材市场的竞争格局复杂多样，既有成熟的医疗设备製造商，也有高度专业化的中型创新企业，以及数量不断成长的科技型Start-Ups。成熟的製造商正凭藉其广泛的销售管道、丰富的监管合规经验和现有的临床关係，迅速拓展分销网络；而小规模的企业则透过推出先进的能量控制演算法、新型可吸收聚合物和紧凑型机器人缝合模组等创新功能，吸引早期采用的外科医生和策略收购公司。

采取切实可行的策略措施和营运策略，加快招募速度，降低价值链风险，并加强临床和商业性价值提案。

产业领导企业应采取一系列协调一致的策略措施，以因应产品设计、市场准入和供应链韧性等问题。首先，应优先考虑模组化产品架构，以实现分阶段升级和简化监理申报流程。这将缩短产品部署时间，并使製造商能够在无需进行重大重新设计的情况下实施针对性改进。其次，应投资于收集将设备性能与临床结果和营运指标连结起来的证据。可操作的临床试验、参与註册研究以及对手术全期工作流程的研究将增强医院和门诊诊所采购产品的合理性。

一个透明的混合方法研究框架，整合了临床医生访谈、监管审查、供应链映射和证据检验验证，以确保获得可靠的见解。

本研究采用混合方法，结合定性一手检验和定量二手资料进行三角验证，对医疗设备的性能、推广应用驱动因素和供应链脆弱性进行了多维度观点。一手调查方法包括对心血管外科医师、采购负责人、临床营运经理和生产主管进行结构化访谈，并辅以手术室观察资料和医疗设备训练模拟资料。这些研究工作获得了关于医疗医疗设备易用性、推广应用挑战和临床医生偏好的第一手资料。

我们透过提供简洁、全面的分析，将临床创新、营运韧性和商业策略连结起来，帮助经营团队在其医疗器材专案中做出稳健的决策。

总之，心血管吻合器材市场正朝着兼顾临床疗效和操作效率的解决方案转变。材料和能源供应方面的创新，以及微创和机器人手术的普及，正在重新定义临床医生对器械的需求，同时也提升了互通性和循证价值提案的重要性。供应链压力和贸易政策的变化进一步凸显了弹性筹资策略和敏捷生产的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 心血管吻合器材市场：依产品类型划分

  • 夹子
    • 止血夹
      • 金属夹
      • 聚合物夹
    • 血管夹
  • 订书机
    • 圆形订书机
    • 直式订书机
      • 未加固型
      • 加强型
  • 缝合装置
    • 自动缝合
      • 手持式缝合器
      • 机器人缝合装置
    • 手工缝合

第九章：心血管吻合装置市场：依机制划分

  • 黏合剂
    • 纤维蛋白胶
    • 合成密封剂
  • 夹钳
  • 压缩
    • 吻合环
    • 扣上
      • 生物可吸收扣
      • 金属扣
  • 能量公式
    • 电暖型
    • 雷射
    • 超音波
  • 装订

第十章：依手术类型分類的心血管吻合器市场

  • 冠状动脉绕道手术
    • 非泵送
    • 泵浦上
  • 週边血管
    • 颈动脉
    • 股腘窝
    • 肾
  • 阀门维修

第十一章：依手术类型分類的心血管吻合器市场

  • 冠状动脉绕道手术手术
    • 心臟外冠状动脉绕道手术绕道手术
    • 非心肺体外迴圈冠状动脉绕道手术手术
    • 微创冠状动脉绕道手术手术
  • 瓣膜手术
    • 主动脉瓣膜手术
    • 二尖瓣手术
    • 三尖瓣和肺动脉瓣手术
  • 主动脉手术
    • 动脉瘤修復手术
    • 分离修復手术
    • 瓣膜根部置换术
  • 先天性心臟疾病手术
    • 室间隔缺损修补术
    • 分流手术
    • 复杂先天性心臟疾病的修復手术
  • 心臟移植及心室辅助装置
    • 心臟移植
    • 植入心室辅助装置
  • 週边血管绕道手术
    • 下肢绕道手术
    • 上肢绕道手术
    • 颈动脉旁路手术
  • 混合治疗和血管内治疗
    • 混合冠状动脉再灌注疗法
    • 主动脉杂交修復术

第十二章 心血管吻合器市场：依最终用户划分

  • 日间手术中心
  • 医院
  • 专科诊所

第十三章 心血管吻合器市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 心血管吻合器材市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 心血管吻合器材市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国心血管吻合装置市场

第十七章：中国心血管吻合器市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Boston Scientific Corporation
  • Cardio Medical GmbH
  • Cook Medical Incorporated
  • CryoLife, Inc.
  • Edwards Lifesciences Corporation
  • Getinge AB
  • Johnson & Johnson
  • LeMaitre Vascular, Inc.
  • LivaNova PLC
  • Medtronic plc
  • Peters Surgical SASU
  • Teleflex Incorporated
  • TERUMO Corporation
  • VasoPrep Surgical, LLC
  • Vitalitec International, Inc.
  • WL Gore & Associates, Inc.
Product Code: MRR-8C74ADFBF9A7

The Cardiovascular Anastomosis Devices Market was valued at USD 2.19 billion in 2025 and is projected to grow to USD 2.43 billion in 2026, with a CAGR of 11.34%, reaching USD 4.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.19 billion
Estimated Year [2026] USD 2.43 billion
Forecast Year [2032] USD 4.65 billion
CAGR (%) 11.34%

A clear and authoritative orientation to the current device ecosystem, clinical considerations, and operational priorities shaping cardiovascular anastomosis today

Cardiovascular anastomosis devices sit at the intersection of surgical technique, materials science, and systems-level healthcare delivery. This introduction frames the contemporary landscape of tools used to establish and secure vascular and cardiac connections during a wide range of procedures, highlighting the ways that device form factors, mechanism of action, and clinical workflows interact to influence outcomes. The discipline has advanced from manual suturing toward mechanized, energy-assisted, and hybrid solutions designed to standardize reproducibility, reduce operative time, and mitigate complications.

Across the portfolio of devices discussed here, clinicians and healthcare organizations increasingly evaluate performance not only by ease of use but by durability, hemostasis efficiency, and compatibility with minimally invasive and robotic approaches. The integration of new polymers, metals, and energy delivery systems has expanded options for surgeons while adding complexity to procurement, training, and regulatory pathways. As stakeholders adopt novel approaches, the balance between device efficacy, clinician ergonomics, and total procedure cost becomes central to commercial conversations.

This introduction sets expectations for the following sections: an analysis of the tectonic shifts reshaping practice, a scenario-based view of tariff impacts, segmentation-driven insights that clarify product and clinical niches, and regional and competitive intelligence designed to inform practical strategy. The aim is to equip decision-makers with clear thematic takeaways that support immediate tactical choices and mid-term strategic planning.

How minimally invasive trends, materials breakthroughs, device interoperability, and evolving procurement models are redefining surgical anastomosis practices

Several transformative shifts are reshaping how cardiovascular anastomosis devices are designed, adopted, and commercialized, with implications that extend across clinical, manufacturing, and reimbursement domains. First, the steady move toward minimally invasive and robotic-assisted surgery has increased demand for devices that provide consistent, reproducible anastomoses within constrained access corridors; this trend is accelerating iterative refinements in form factor, articulation, and integration with robotic platforms. As a result, product development now emphasizes modular interfaces and compatibility standards that allow quicker clinical adoption and lower training burden.

Second, materials innovation-ranging from polymer formulations for absorbable components to new alloys and coatings for hemostatic clips-has expanded device longevity and biocompatibility while enabling engineers to reduce profile footprint and improve deployment reliability. Concurrently, energy-based technologies such as electrothermal and ultrasonic modalities are being refined to deliver controlled tissue effects, reducing bleeding and shortening operative time when properly matched to the clinical indication.

Third, procurement dynamics are evolving as ambulatory surgery centers gain greater procedural volume and hospitals pursue value-based metrics; this has heightened focus on total procedural cost, inventory optimization, and interoperability with existing devices. Lastly, regulatory and clinical-evidence expectations are rising, driving firms to invest in robust comparative studies and real-world evidence generation that demonstrate not only safety and efficacy but also downstream economic and workflow benefits. Taken together, these forces are producing a market environment where technical differentiation, clinical validation, and distribution agility determine the leaders in device adoption.

A practical analysis of how evolving US tariff dynamics drive supply chain reengineering, pricing pressure, and opportunities for local manufacturing resilience

The imposition and escalation of tariffs originating from policy shifts in major markets can materially influence supply chain choices, sourcing strategies, and component economics for manufacturers and distributors of cardiovascular anastomosis devices. When import levies are introduced or increased, firms that rely on cross-border sourcing for precision metal components, advanced polymers, electronic control units, or robotic subsystems must reassess supplier relationships and inventory practices to maintain margin and availability.

In practical terms, tariffs often catalyze near-term cost passthrough to buyers or compression of supplier margins, creating pressure to redesign devices for fewer tariff-sensitive inputs or to qualify local manufacturers who can supply key subassemblies. Manufacturers may pursue regional production hubs or toll-manufacturing agreements to mitigate exposure to targeted levies. At the same time, elevated import costs can accelerate vertical integration for components with high tariff risk, prompting manufacturers to acquire or partner with specialized suppliers to secure continuity and reduce unit cost volatility.

Clinically, procurement teams and hospital systems respond to tariff-driven price changes by tightening evaluation criteria, increasing competitive bidding, and prioritizing multi-use or reusable solutions where appropriate. Reimbursement administrators and value committees may demand clearer evidence of cost-benefit under new input-cost realities. For innovation-driven companies, tariffs create both challenges and opportunities: while they can increase near-term commercial friction, they also incentivize product simplification, localization of sensitive supply chains, and the development of incremental improvements that reduce reliance on imported materials and finished goods. Thus, tariff scenarios should be integrated into strategic planning as an ongoing supply-chain and pricing risk that requires coordinated responses across procurement, regulatory affairs, and product development.

A multi-dimensional segmentation synthesis that aligns product type, mechanism, procedure, and end-user parameters to reveal precise clinical and commercial target zones

Understanding product and clinical niches requires a layered segmentation approach that clarifies where innovation and commercialization can most effectively be targeted. By product type, the device universe encompasses clips, staplers, and suture devices. Clips are used for rapid vessel control and are typified by hemostatic clips and ligating clips; hemostatic clips themselves are delivered in metal and polymer variants that trade off permanence and imaging compatibility. Staplers include circular and linear configurations, and within linear staplers manufacturers distinguish between non-reinforced and reinforced variants to address tissue thickness and leak resistance. Suture devices span automated suturing and manual suturing techniques, with the automated category further divided into handheld suturators and robotic suturators that target different levels of automation and procedural complexity.

By mechanism of action, devices are organized across adhesive solutions, clamping systems, compression mechanisms, energy-based modalities, and stapling. Adhesive technologies include biologic fibrin sealants and synthetic sealants, each offering distinct handling and hemostatic profiles. Compression strategies cover anastomotic rings and buckles, and buckles may be bioabsorbable or metal depending on the intended permanence. Energy-based devices deploy electrothermal, laser, or ultrasonic effects to seal tissue and control bleeding while minimizing collateral thermal injury.

By procedure type, device selection aligns with the clinical context: coronary bypass surgery-performed off-pump or on-pump-creates one set of anastomotic challenges, whereas peripheral vascular procedures such as carotid, femoropopliteal, and renal interventions demand devices optimized for vessel size, accessibility, and plaque burden. Valve repair procedures introduce additional anatomical and hemodynamic constraints that influence device selection and deployment technique. Finally, end-user segmentation highlights the delivery environment: ambulatory surgery centers, hospitals, and specialty clinics each impose distinct requirements in terms of device footprint, sterilization workflows, and staff training. Appreciating these interlocking segmentation layers enables firms to tailor product design, clinical evidence generation, and commercialization pathways to the realities of distinct clinical and operational settings.

How regional clinical priorities, regulatory environments, and supply chain footprints differentially influence device adoption across Americas, EMEA, and Asia-Pacific

Regional dynamics shape adoption pathways, regulatory hurdles, and supply-chain design in ways that affect strategy and execution. In the Americas, clinical emphasis on minimally invasive coronary and peripheral interventions intersects with a mature reimbursement infrastructure and sophisticated hospital purchasing processes. Providers in major markets prioritize devices that demonstrably reduce operating time, lower complication rates, and integrate with existing surgical platforms. Meanwhile, regional manufacturers and contract manufacturers play a significant role in providing localized supply and rapid replenishment, which benefits high-volume centers.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory alignment across countries and strong national procurement agencies can accelerate adoption when evidence is compelling, but fragmentation across markets requires tailored regulatory and reimbursement strategies. Several European markets have high expectations for real-world evidence and cost-effectiveness data, and procurement bodies often demand long-term safety information for devices intended to be permanent or semi-permanent.

Asia-Pacific is characterized by rapid growth in procedural volumes, expanding investment in hospital infrastructure, and a dual market structure that includes both high-end tertiary care centers and resource-constrained facilities. Local OEMs and regional supply chains are increasingly sophisticated, and multinational vendors often pursue partnerships or local production to meet regulatory and cost requirements. Across regions, companies that align product portfolios to local procedural patterns, regulatory timing, and purchasing models gain the clearest path to sustained adoption.

An incisive review of competitive positioning, partnership dynamics, supplier concentration, and the innovation pathways shaping device leadership

Competitive dynamics in cardiovascular anastomosis devices are shaped by a mix of incumbent medical-device firms, specialized mid-sized innovators, and a growing cohort of technology-focused startups. Established manufacturers leverage broad commercial channels, regulatory experience, and existing clinical relationships to scale distribution quickly, while smaller players advance disruptive features-such as advanced energy control algorithms, novel absorbable polymers, or compact robotic suturing modules-that attract early-adopter surgeons and strategic acquirers.

Partnerships and co-development agreements between device companies and robotic platform providers have intensified as both sides seek to ensure interoperability and bundled clinical value propositions. Cross-disciplinary collaboration between materials scientists, clinical researchers, and systems engineers has produced a pipeline of incremental innovations that improve handling, reduce device profile, and enhance hemostasis. At the same time, regulatory pathways emphasizing clinical evidence and post-market surveillance have raised the bar for new entrants, making clinical trial design, registry participation, and formal health-economics analysis essential components of go-to-market plans.

Supplier concentration for specialized components-precision stamping for metal clips, custom polymer extrusion, and microelectronics for energy delivery systems-creates strategic dependencies that influence pricing and lead times. Consequently, firms that maintain diversified supplier bases, invest in secondary sourcing, or internalize key capabilities are better positioned to manage disruption. Competitive advantage increasingly accrues to organizations that can pair clinical efficacy with demonstrable workflow improvements and clear economic narratives that resonate with hospital administrators and integrated delivery networks.

Practical strategic moves and operational measures to accelerate adoption, de-risk supply chains, and strengthen clinical and commercial value propositions

Industry leaders should adopt a coordinated set of strategic actions that address product design, commercial access, and supply-chain resilience. First, prioritize modular product architectures that enable incremental upgrades and simplified regulatory submissions; this reduces time-to-adoption and allows manufacturers to introduce targeted improvements without broad redesign. Second, invest in evidence generation that links device performance to clinical outcomes and operational metrics; pragmatic trials, registry participation, and perioperative workflow studies will strengthen purchasing cases in both hospitals and ambulatory centers.

Third, diversify sourcing and consider regional manufacturing footprints to mitigate tariff exposure and logistics risk; dual-sourcing agreements, qualified contract manufacturers in strategic geographies, and selective vertical integration for high-risk components will reduce vulnerability to trade disruptions. Fourth, enhance surgeon training pathways through simulation, proctoring networks, and digital learning platforms to accelerate clinician confidence and shorten the adoption curve for new devices or techniques. Fifth, tailor commercial models to end-user needs by offering bundled procedural kits for ambulatory centers and specialized support packages for high-acuity hospitals, thereby aligning value propositions with purchaser incentives.

Finally, maintain an active regulatory engagement plan and monitor evolving standards for energy-based and implantable components. Engaging early with regulators and reimbursement stakeholders can expedite market access while ensuring that clinical data collection supports long-term surveillance and economic assessment. Together, these actions form a pragmatic roadmap that balances near-term operational resilience with long-term clinical and commercial differentiation.

A transparent mixed-methods research framework integrating clinician interviews, regulatory review, supply-chain mapping, and evidence triangulation to ensure robust insights

The research applied a mixed-methods approach that triangulated primary qualitative engagement with quantitative secondary data to build a multi-perspective view of device performance, adoption drivers, and supply-chain vulnerabilities. Primary inputs included structured interviews with cardiac and vascular surgeons, procurement officers, clinical affairs leaders, and manufacturing executives, supplemented by observational inputs from procedure rooms and device training simulations. These engagements provided first-hand insights into device usability, deployment challenges, and clinician preferences.

Secondary research encompassed systematic reviews of peer-reviewed clinical literature, regulatory filings, patent landscapes, and technology white papers to validate performance claims and trace innovation trajectories. Supply-chain mapping combined customs data, supplier directories, and manufacturing footprint analysis to identify concentration risks and potential nearshoring opportunities. Methodological rigor was ensured through cross-validation of findings across multiple data sources, sensitivity testing of scenario assumptions, and advisory review by clinical and industry experts.

Ethical research practices were observed throughout, and proprietary data were handled under strict confidentiality protocols. The synthesis prioritized actionable intelligence that speaks directly to procurement, R&D, and commercial planning needs without relying on unverifiable claims, ensuring that recommendations are grounded in observable trends and corroborated practitioner experience.

A concise synthesis linking clinical innovation, operational resilience, and commercial strategy to inform confident executive decision-making in device programs

In closing, the cardiovascular anastomosis device landscape is transitioning toward solutions that harmonize clinical efficacy with operational efficiency. Innovations in materials and energy delivery, along with the spread of minimally invasive and robotic approaches, are redefining what clinicians expect from devices while amplifying the importance of interoperability and evidence-based value propositions. Supply-chain pressures and trade-policy shifts further underscore the need for flexible sourcing strategies and manufacturing agility.

Decision-makers who align product development with clear procedural needs, invest in rigorous clinical and economic evidence, and adopt resilient manufacturing and procurement practices will be best positioned to capture sustainable adoption. Equally, organizations that prioritize end-user training, simplified device interfaces, and targeted regional strategies can accelerate uptake in high-opportunity clinical segments. The synthesis presented here is intended to inform tactical choices and strategic investment priorities that drive both improved patient outcomes and durable commercial performance.

By bringing clinical insight, supply-chain realism, and competitive clarity together, this analysis supports executives and clinical leaders in making measured, high-confidence decisions about where to invest, how to mitigate risk, and how to scale innovations across diverse healthcare settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiovascular Anastomosis Devices Market, by Product Type

  • 8.1. Clips
    • 8.1.1. Hemostatic Clips
      • 8.1.1.1. Metal Clips
      • 8.1.1.2. Polymer Clips
    • 8.1.2. Ligating Clips
  • 8.2. Staplers
    • 8.2.1. Circular Staplers
    • 8.2.2. Linear Staplers
      • 8.2.2.1. Non Reinforced
      • 8.2.2.2. Reinforced
  • 8.3. Suture Devices
    • 8.3.1. Automated Suturing
      • 8.3.1.1. Handheld Suturer
      • 8.3.1.2. Robotic Suturer
    • 8.3.2. Manual Suturing

9. Cardiovascular Anastomosis Devices Market, by Mechanism

  • 9.1. Adhesive
    • 9.1.1. Fibrin Sealants
    • 9.1.2. Synthetic Sealants
  • 9.2. Clamping
  • 9.3. Compression
    • 9.3.1. Anastomotic Rings
    • 9.3.2. Buckles
      • 9.3.2.1. Bioabsorbable Buckles
      • 9.3.2.2. Metal Buckles
  • 9.4. Energy Based
    • 9.4.1. Electrothermal
    • 9.4.2. Laser
    • 9.4.3. Ultrasonic
  • 9.5. Stapling

10. Cardiovascular Anastomosis Devices Market, by Procedure Type

  • 10.1. Coronary Bypass
    • 10.1.1. Off Pump
    • 10.1.2. On Pump
  • 10.2. Peripheral Vascular
    • 10.2.1. Carotid
    • 10.2.2. Femoropopliteal
    • 10.2.3. Renal
  • 10.3. Valve Repair

11. Cardiovascular Anastomosis Devices Market, by Surgery Type

  • 11.1. Coronary Artery Bypass Grafting
    • 11.1.1. On-Pump Coronary Bypass
    • 11.1.2. Off-Pump Coronary Bypass
    • 11.1.3. Minimally Invasive Coronary Bypass
  • 11.2. Valve Surgery
    • 11.2.1. Aortic Valve Procedures
    • 11.2.2. Mitral Valve Procedures
    • 11.2.3. Tricuspid And Pulmonic Valve Procedures
  • 11.3. Aortic Surgery
    • 11.3.1. Aneurysm Repair
    • 11.3.2. Dissection Repair
    • 11.3.3. Root Replacement
  • 11.4. Congenital Heart Surgery
    • 11.4.1. Septal Defect Repair
    • 11.4.2. Shunt Procedures
    • 11.4.3. Complex Congenital Repairs
  • 11.5. Heart Transplant And Ventricular Assist Device
    • 11.5.1. Heart Transplant
    • 11.5.2. Ventricular Assist Device Implantation
  • 11.6. Peripheral Vascular Bypass
    • 11.6.1. Lower Extremity Bypass
    • 11.6.2. Upper Extremity Bypass
    • 11.6.3. Carotid Bypass
  • 11.7. Hybrid And Endovascular Procedures
    • 11.7.1. Hybrid Coronary Revascularization
    • 11.7.2. Aortic Hybrid Repair

12. Cardiovascular Anastomosis Devices Market, by End User

  • 12.1. Ambulatory Surgery Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Cardiovascular Anastomosis Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cardiovascular Anastomosis Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cardiovascular Anastomosis Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cardiovascular Anastomosis Devices Market

17. China Cardiovascular Anastomosis Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. B. Braun Melsungen AG
  • 18.7. Baxter International Inc.
  • 18.8. Boston Scientific Corporation
  • 18.9. Cardio Medical GmbH
  • 18.10. Cook Medical Incorporated
  • 18.11. CryoLife, Inc.
  • 18.12. Edwards Lifesciences Corporation
  • 18.13. Getinge AB
  • 18.14. Johnson & Johnson
  • 18.15. LeMaitre Vascular, Inc.
  • 18.16. LivaNova PLC
  • 18.17. Medtronic plc
  • 18.18. Peters Surgical SASU
  • 18.19. Teleflex Incorporated
  • 18.20. TERUMO Corporation
  • 18.21. VasoPrep Surgical, LLC
  • 18.22. Vitalitec International, Inc.
  • 18.23. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SURGERY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL CLIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY POLYMER CLIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LIGATING CLIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CIRCULAR STAPLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY NON REINFORCED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REINFORCED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HANDHELD SUTURER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROBOTIC SUTURER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MANUAL SUTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FIBRIN SEALANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SYNTHETIC SEALANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLAMPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANASTOMOTIC RINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BIOABSORBABLE BUCKLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY METAL BUCKLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ELECTROTHERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LASER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ULTRASONIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY FEMOROPOPLITEAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY RENAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SURGERY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON-PUMP CORONARY BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON-PUMP CORONARY BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ON-PUMP CORONARY BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF-PUMP CORONARY BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF-PUMP CORONARY BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY OFF-PUMP CORONARY BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MINIMALLY INVASIVE CORONARY BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MINIMALLY INVASIVE CORONARY BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MINIMALLY INVASIVE CORONARY BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC VALVE PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC VALVE PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC VALVE PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MITRAL VALVE PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MITRAL VALVE PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MITRAL VALVE PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY TRICUSPID AND PULMONIC VALVE PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY TRICUSPID AND PULMONIC VALVE PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY TRICUSPID AND PULMONIC VALVE PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANEURYSM REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANEURYSM REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ANEURYSM REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY DISSECTION REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY DISSECTION REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY DISSECTION REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROOT REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROOT REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ROOT REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CONGENITAL HEART SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CONGENITAL HEART SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CONGENITAL HEART SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CONGENITAL HEART SURGERY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SEPTAL DEFECT REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SEPTAL DEFECT REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SEPTAL DEFECT REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SHUNT PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SHUNT PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SHUNT PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPLEX CONGENITAL REPAIRS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPLEX CONGENITAL REPAIRS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPLEX CONGENITAL REPAIRS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT AND VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT AND VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT AND VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT AND VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VENTRICULAR ASSIST DEVICE IMPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VENTRICULAR ASSIST DEVICE IMPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VENTRICULAR ASSIST DEVICE IMPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR BYPASS, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LOWER EXTREMITY BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LOWER EXTREMITY BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LOWER EXTREMITY BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY UPPER EXTREMITY BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY UPPER EXTREMITY BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY UPPER EXTREMITY BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CAROTID BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID AND ENDOVASCULAR PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID AND ENDOVASCULAR PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID AND ENDOVASCULAR PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID AND ENDOVASCULAR PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID CORONARY REVASCULARIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID CORONARY REVASCULARIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID CORONARY REVASCULARIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC HYBRID REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC HYBRID REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC HYBRID REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, 2018-2032 (USD MILLION)
  • TABLE 240. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, 2018-2032 (USD MILLION)
  • TABLE 241. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SURGERY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 243. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 244. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 245. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CONGENITAL HEART SURGERY, 2018-2032 (USD MILLION)
  • TABLE 246. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT AND VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 247. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR BYPASS, 2018-2032 (USD MILLION)
  • TABLE 248. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID AND ENDOVASCULAR PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 249. AMERICAS CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CLIPS, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEMOSTATIC CLIPS, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY STAPLERS, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY LINEAR STAPLERS, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SUTURE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AUTOMATED SUTURING, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ADHESIVE, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY COMPRESSION, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY BUCKLES, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY ENERGY BASED, 2018-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY BYPASS, 2018-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR, 2018-2032 (USD MILLION)
  • TABLE 266. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY SURGERY TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 268. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY VALVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY AORTIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 270. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY CONGENITAL HEART SURGERY, 2018-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HEART TRANSPLANT AND VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 272. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR BYPASS, 2018-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA CARDIOVASCULAR ANASTOMOSIS DEVICES MARKET SIZE, BY HYBRID AN